Regentis Biomaterials Ltd.
RGNT- Exchange
- NYSE
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- SEC CIK
- 0001912966
No open-market purchases or sales by Regentis Biomaterials Ltd. insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $2.98M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Regentis Biomaterials Ltd. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 3 | 3 | 0 |
| Shares | 281.0K | 551.8K | +270.8K (+96.4%) |
| Value | $1.89M | $1.69M | −$206.4K (−10.9%) |
New holders (2)
Institutions that held Regentis Biomaterials Ltd. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AIGH Capital Management LLC | 300,000 | $916.5K | 0.19% |
| UBS Group AG | 334 | $1.02K | 0.00% |
Sold out (2)
Institutions that held Regentis Biomaterials Ltd. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Warberg Asset Management LLC | 19,093 | $127.0K |
| Citadel Advisors LLC | 10,412 | $70.2K |